STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARGX
  4. [6-K] ARGENX SE Current Report (Foreign Issuer)

argenx (ARGX) schedules FcRn-focused autoimmune myositis R&D webinar

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

argenx filed a Form 6-K to share a press release about an upcoming research and development webinar on autoimmune myositis. The event, titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis,” will take place on June 23, 2026, at 2:00pm ET.

The webinar will feature argenx management, scientific leaders and external experts, and will be webcast live on the company’s investor website, with a replay available for about one year. Supporting presentation slides and other materials will be posted on the Events & Presentations section of the argenx website.

Positive

  • None.

Negative

  • None.
Webinar date June 23, 2026 Date of autoimmune myositis R&D webinar
Webinar time 2:00pm ET Scheduled start time of live webinar
Replay availability Approximately one year Duration replay will remain on argenx website
Webcast announcement time 7:00 AM CET Press release timestamp from Amsterdam
Form 6-K regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
foreign private issuer regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
autoimmune myositis medical
"R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis"
Autoimmune myositis is a group of conditions in which the immune system mistakenly attacks and inflames skeletal muscles, causing progressive weakness, fatigue, and reduced mobility; think of the immune system acting like a security guard that targets the body’s own muscle tissue. It matters to investors because it creates a defined market for diagnostic tests, long‑term treatments and clinical trials, so disease prevalence, therapy effectiveness, safety profiles and regulatory outcomes directly affect healthcare spending and the commercial prospects of drug developers.
neonatal Fc receptor (FcRn) medical
"the first approved neonatal Fc receptor (FcRn) blocker"
Neonatal Fc receptor (FcRn) is a protein in the body that binds and protects certain antibodies from being broken down, effectively acting like a recycling center that extends their lifespan and helps move them between tissues. For investors, FcRn matters because medicines that target or use this receptor can change how long antibody drugs last or reduce harmful antibodies in autoimmune diseases, affecting dosing, effectiveness, safety and commercial value.
Immunology Innovation Program (IIP) financial
"Partnering with leading academic researchers through its Immunology Innovation Program (IIP)"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of June 2026

 

Commission File Number: 001-38097

 

 

ARGENX SE

(Translation of registrant’s name into English)

 

 

Laarderhoogtweg 25
1101 EB Amsterdam, the Netherlands

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x     Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

 

 

EXPLANATORY NOTE

 

On June 23, 2026, argenx SE (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

The information contained in this Current Report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the Company’s Registration Statements on Forms S-8 (File Nos. 333-225375, 333-258253, 333-274721, and 333-292200), and to be part thereof from the date on which this Current Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Exhibit   Description
     
99.1   Press Release June 23, 2026

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ARGENX SE
     
Date: June 23, 2026 By:  /s/ Hemamalini (Malini) Moorthy
   

Name: Hemamalini (Malini) Moorthy

Title: General Counsel

 

 

 

 

Exhibit 99.1

 

 

argenx to Host Autoimmune Myositis R&D Webinar

 

June 23, 2026, 7:00 AM CET

 

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host a webinar titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” today, June 23, 2026, at 2:00pm ET.

 

argenx management and scientific leadership will be joined by external key opinion leaders:

 

·Avery LaChance, MD, MPH, FAAD, Associate Professor of Dermatology, Harvard Medical School; Director of Connective Tissue Disease Clinic

 

·Arjun Seth, MD, Assistant Professor, Neurology (Neuromuscular Disease), Northwestern University Feinberg School of Medicine

 

·Rohit Aggarwal, MD, MS, Professor of Medicine, University of Pittsburgh, and Co-Director of UPMC Myositis Center

 

Webcast Information

 

A live webcast of the event can be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

 

Additional materials, including supporting presentation slides, will be available on argenx’s Events & Presentations website today at 2:00pm ET.

 

About argenx

 

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  www.argenx.com  and follow us on LinkedIn, Instagram, Facebook, and YouTube.

 

Contacts

 

Media:

Colin McBean

cmcbean@argenx.com

 

Investors:

Alexandra Roy

aroy@argenx.com

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What did argenx (ARGX) announce in its June 2026 Form 6-K?

argenx announced an R&D webinar on autoimmune myositis titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis.” The event highlights its FcRn-focused research and will be accessible via live webcast and replay on the company’s investor website.

When is the argenx (ARGX) autoimmune myositis R&D webinar scheduled?

The autoimmune myositis R&D webinar is scheduled for June 23, 2026, at 2:00pm ET. argenx will host the session with internal leaders and external experts, focusing on advancing its FcRn leadership in serious autoimmune diseases.

How can investors access the argenx (ARGX) autoimmune myositis webinar?

Investors can access a live webcast of the webinar via the Investors section of argenx.com. A replay will be available on the site for approximately one year, along with supporting presentation materials under Events & Presentations.

What is the focus of argenx’s autoimmune myositis R&D webinar?

The webinar focuses on “Advancing FcRn Leadership into Autoimmune Myositis,” reflecting argenx’s work with its neonatal Fc receptor (FcRn) blocker. Management, scientists and external key opinion leaders will discuss its potential in severe autoimmune diseases.

What business does argenx (ARGX) describe in this Form 6-K press release?

argenx describes itself as a global immunology company developing novel antibody-based medicines for severe autoimmune diseases. It has developed and is commercializing an approved neonatal Fc receptor (FcRn) blocker and is advancing additional experimental medicines.

Filing Exhibits & Attachments

1 document

Press Releases